C. Kollmannsberger

发表

Canadian guideline on genetic screening for hereditary renal cell

S. Pautler, A. Pause, G. Bjarnason, 2013 .

tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial

A. Horwich, J. Gampe, K. Oechsle, 2011 .

Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.

C. Bokemeyer, L. Kanz, C. Kollmannsberger, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience

C. Bokemeyer, U. Jonas, M. Kuczyk, 2002, BJU international.

Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.

C. Meisner, C. Bokemeyer, L. Kanz, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases.

C. Bokemeyer, L. Kanz, U. Rüther, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies

C. Bokemeyer, L. Kanz, C. Kollmannsberger, 1998, Journal of Cancer Research and Clinical Oncology.

Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy.

S. Daneshmand, B. Hayes-Lattin, C. Moore, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies.

G. Duncan, S. Daneshmand, B. Hayes-Lattin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.

J. Christensen, G. Shapiro, H. Hurwitz, 2015 .

Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.

M. Smylie, S. Verma, C. Kollmannsberger, 2018, Current oncology.

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.

C. Bokemeyer, K. Oechsle, F. Mayer, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Absence of c‐KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer

C. Bokemeyer, L. Kanz, F. Mayer, 2002, Cancer.

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

C. Bokemeyer, L. Kanz, F. Mayer, 2002, British Journal of Cancer.

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

J Schleicher, C. Bokemeyer, L. Kanz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.

C. Bokemeyer, K. Oechsle, F. Mayer, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial

C. Bokemeyer, L. Kanz, N. Schleucher, 2003, British Journal of Cancer.

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer

C. Bokemeyer, M. Schittenhelm, F. Mayer, 2013, Investigational New Drugs.

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

A. Tolcher, B. Kaiser, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Late toxicity after treatment for testicular germ cell cancer

C. Bokemeyer, L. Kanz, C. Kollmannsberger, 1998, Der Urologe.

A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer.

S. Ellard, R. Carr, L. Lê, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

F. Saad, A. Kapoor, S. Hotte, 2011, Current oncology.

A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

C. Bokemeyer, L. Kanz, C. Kollmannsberger, 2000, British Journal of Cancer.

Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET

C. Claussen, C. Bokemeyer, L. Kanz, 2002, British Journal of Cancer.